Evaluation of the association of polymorphisms of the CYP2C8 gene with the efficacy and safety of ketorolac in patients with postoperative pain syndrome
- 作者: Muradian A.1, Sychev D.1, Blagovestnov D.1, Petrov D.1, Skukin D.2, Epifanova I.1, Sozaeva Z.1, Kachanova A.1, Denisenko N.1, Abdullaev S.1, Grishina E.1
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education
- Sklifosovsky Research Institute of Emergency Medicine
- 期: 卷 94, 编号 5 (2022)
- 页面: 610-615
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/108776
- DOI: https://doi.org/10.26442/00403660.2022.05.201495
- ID: 108776
如何引用文章
全文:
详细
Aim. To evaluate the possible association of CYP2C8 gene polymorphisms with the clinical efficacy and safety of ketorolac in relation to postoperative pain.
Materials and methods. The study included 107 patients after video laparoscopic cholecystectomy, who received ketorolac (30 mg 2.0 w/m 3 r/d) as postoperative pain relief. All patients were genotyped for CYP2C8. The pain syndrome was assessed using the visual analog scale, the McGill pain questionnaire. The profile of adverse reactions was assessed by the dynamics of red blood counts, as a possible trigger for the development of gastrointestinal bleeding according to the method of global assessment of triggers (Global Trigger Tool – GTT).
Results. According to visual analog scale data: in carriers of the genotype CYP2C8*3 (rs10509681) and CYP2C8*3 (rs11572080) after 12, 24, 36, 48 hours the intensity of pain syndrome is lower than in carriers of the wild type (p<0.05). According to the McGill pain questionnaire, there were no statistically significant differences in pain intensity between the two groups.
Conclusion. In carriers of the genotype CYP2C8*3 (rs10509681) and CYP2C8*3 (rs11572080), the effectiveness of anesthesia with ketorolac is higher than in carriers of the wild type. Carriage of the genotype CYP2C8*3 (rs10509681) and CYP2C8*3 (rs10509681) does not affect the risk of developing adverse reactions after ketorolac anesthesia.
作者简介
Andranik Muradian
Russian Medical Academy of Continuous Professional Education
编辑信件的主要联系方式.
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0003-4367-637X
канд. мед. наук, ассистент каф. неотложной и общей хирургии ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowDmitry Sychev
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0002-4496-3680
чл.-кор. РАН, д-р мед. наук, проф., ректор ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowDmitry Blagovestnov
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0001-5724-6034
д-р мед. наук, проф., декан хирургического фак-та ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowDemyan Petrov
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0001-7665-0163
канд. мед. наук, ассистент каф. неотложной и общей хирургии ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowDmitry Skukin
Sklifosovsky Research Institute of Emergency Medicine
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0003-0475-7441
врач-хирург хирургического отд-ния ГБУЗ «НИИ СП им. Н.В. Склифосовского»
俄罗斯联邦, MoscowIrina Epifanova
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0003-0892-7153
ст. лаборант каф. неотложной и общей хирургии ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowZhannet Sozaeva
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0001-5166-7903
мл. науч. сотр. отд. молекулярной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowAnastasia Kachanova
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0003-3194-4410
мл. науч. сотр. отд. молекулярной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowNatalia Denisenko
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0003-3278-5941
канд. мед. наук, зав. отд. персонализированной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowSherzod Abdullaev
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0001-9001-1499
канд. биол. наук, зав. отд. молекулярной медицины Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowElena Grishina
Russian Medical Academy of Continuous Professional Education
Email: andranik_muradian@mail.ru
ORCID iD: 0000-0002-5621-8266
д-р биол. наук, доц., дир. Научно-исследовательского института молекулярной и персонализированной медицины ФГБОУ ДПО РМАНПО
俄罗斯联邦, Moscow参考
- Каратеев А.Е., Насонов Е.Л., Яхно Н.Н., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1)1:4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Modern Rheumatology Journal. 2015;9(1):4-23 (in Russian)]. doi: 10.14412/1996-7012-2015-1-4-23
- Ladak SSJ, Chan VWS, Easty T, Chagpar A. Right Medication, Right Dose, Right Patient, Right Time, and Right Route: How Do We Select the Right Patient-Controlled Analgesia (PCA) Device? Pain Manag Nurs. 2007;8(4):140-5. doi: 10.1016/j.pmn.2007.08.001
- Кукес В.Г., Сычев Д.А., Раменская Г.В., Игнатьев И.В. Фармакогенетика системы биотрансформации и транспортеров лекарственных средств : от теории к практике. Биомедицина. 2007;6:29-47 [Kukes VG, Sychev DA, Ramenskaya GV, Ignat'ev IV. Pharmacogenetics of system of biotransformation and drugs transporters: from the theory to practice. Biomeditsina. 2007;6:29-47 (in Russian)].
- Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257-65. doi: 10.1038/sj.tpj.6500406
- Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008;4(1):77-91. doi: 10.1517/17425255.4.1.77
- Ko TM, Wong CS, Wu JY, Chen YT. Pharmacogenomics for personalized pain medicine. Acta Anaesthesiol Taiwan. 2016;54(1):24-30. doi: 10.1016/j.aat.2016.02.001
- Flores CM, Mogil JS. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics. 2001;2(3):177-94. doi: 10.1517/14622416.2.3.177
- Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010;278(2):165-88. doi: 10.1016/j.tox.2009.08.013
- Martínez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2):205-8. doi: 10.1038/sj.bjp.0705623
- Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465-71. doi: 10.1053/j.gastro.2007.05.025
- Blanco G, Martínez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics. 2008;18(1):37-43. doi: 10.1097/FPC.0b013e3282f305a9
- Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33(11):1567-75. doi: 10.1124/dmd.105.006452
- Rollason V, Samer CF, Daali Y, Desmeules JA. Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti-Inflammatory Drugs: A Review. Curr Drug Metab. 2014;15(3):326-43. doi: 10.2174/1389200215666140202214454
- Agúndez JAG, García-Martín E, Martínez C. Genetically based impair-ment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009;5(6):607-20. doi: 10.1517/17425250902970998
- Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. Eur J Clin Pharmacol. 2013;69(7):1369-73. doi: 10.1007/s00228-013-1477-9
- Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272-81. doi: 10.1053/j.gastro.2006.11.023
- Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol. 2001;57(10):729-35. doi: 10.1007/s00228-001-0376-7
- García-Martín E, Martínez C, Tabarés B, et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004;76(2):119-27. doi: 10.1016/j.clpt.2004.04.006
- Martínez C, García-Martín E, Blanco G, et al. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol. 2005;59(1):62-9. doi: 10.1111/j.1365-2125.2004.02183.x
- Arnaldo P, Thompson RE, Lopes MQ, et al. Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population. Malays J Med Sci. 2013;20(4):12-23.
- Lopez-Rodriguez R, Novalbos J, Gallego-Sandin S, et al. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res. 2008;58(1):77-84. doi: 10.1016/j.phrs.2008.07.004
- Menahem B, Mulliri A, Fohlen A, et al. Delayed laparoscopic cholecystectomy increases the total hospital stay compared to an early laparoscopic cholecystectomy after acute cholecystitis: an updated meta-analysis of randomized controlled trials. HPB (Oxford). 2015;17(10):857-62. doi: 10.1111/hpb.12449